Coya Therapeutics, Inc. (COYA)
| Market Cap | 98.84M |
| Revenue (ttm) | 3.69M |
| Net Income (ttm) | -17.14M |
| Shares Out | 16.72M |
| EPS (ttm) | -1.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 62,345 |
| Open | 5.79 |
| Previous Close | 5.79 |
| Day's Range | 5.74 - 5.93 |
| 52-Week Range | 4.65 - 10.24 |
| Beta | 0.22 |
| Analysts | Strong Buy |
| Price Target | 16.67 (+182.06%) |
| Earnings Date | Aug 11, 2025 |
About COYA
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic l... [Read more]
Financial Performance
In 2024, Coya Therapeutics's revenue was $3.55 million, a decrease of -40.79% compared to the previous year's $6.00 million. Losses were -$14.88 million, 86.3% more than in 2023.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for COYA stock is "Strong Buy." The 12-month stock price forecast is $16.67, which is an increase of 182.06% from the latest price.
News
Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya”) today announced the issuance of a U.S. patent relevant to its investigational ready-to-use (RTU) liquid formulation of IL-2. I...
Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors
Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the ...
Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release
Positive interim data by Coya Therapeutics released from 5 patients in an investigator-initiated proof-of-concept study using COYA-302 for the treatment of patients with FTD. An IND filing and phase 2...
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD
Coya Therapeutics, Inc. has Treg therapies for neurodegenerative and autoimmune diseases, targeting ALS, FTD, AD, and PD. However, their lead candidate is now clearly COYA 302. This drug basically com...
Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch
Potential initiation of phase 2b study using COYA-302 for the treatment of patients with Amyotrophic Lateral Sclerosis, expected in 2025 barring successful IND clearance by the FDA. Biomarker data fro...
Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing
On Thursday, Coya Therapeutics, Inc. COYA announced blood biomarker data from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of LD IL-2 in patients wit...
Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the ...
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off
Coya Therapeutics, Inc.'s stock has sold off on misinterpreted data from a small trial with COYA 301. The presented clinical data validates safety, tolerability, and the inverse dose response of IL-2 ...